Related Experiment Video
Updated: Jun 18, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
Marcin Kubeczko1, Dorota Gabryś2, Anna Polakiewicz-Gilowska1
1Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
Summary
Locoregional radiotherapy (RT) combined with first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in advanced breast cancer shows potential. High-dose RT may improve progression-free survival, but palliative doses might be insufficient for local control.
Area of Science:
- Oncology
- Radiotherapy
- Medical Physics
Background:
- Locoregional radiotherapy (RT) use in advanced ER-positive, HER2-negative breast cancer is debated.
- Evaluating RT efficacy with first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is crucial.
Purpose of the Study:
- To assess the efficacy of locoregional RT in advanced breast cancer patients treated with CDK4/6i.
- To determine the impact of RT on progression-free survival (PFS) and local control.
Main Methods:
- Retrospective analysis of advanced breast cancer patients (2018-2023).
- Patients received first-line CDK4/6i with or without locoregional RT.
- Comparison of outcomes based on RT dose and prior RT history.
Main Results:
- Among 371 patients on CDK4/6i, 23 received locoregional RT.
- Local progression occurred in 5.1% of patients, higher in those with prior RT (21.7% vs 4.0%).
- Two-year PFS was 65.7%; higher RT doses showed a trend towards better PFS (83.3% vs 59.3%) and no local progression.
Conclusions:
- Adding locoregional RT to first-line CDK4/6i warrants further investigation.
- Palliative RT doses may be insufficient for local control in oligoprogression.
- Comprehensive studies are needed to define optimal RT strategies in advanced breast cancer.
Related Concept Videos
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K